Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Receivables (2016 - 2025)

BioCorRx's Receivables history spans 16 years, with the latest figure at $955957.0 for Q3 2025.

  • For Q3 2025, Receivables rose 52.14% year-over-year to $955957.0; the TTM value through Sep 2025 reached $955957.0, up 52.14%, while the annual FY2023 figure was $152532.0, 39.66% down from the prior year.
  • Receivables for Q3 2025 was $955957.0 at BioCorRx, up from $204970.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.1 million in Q1 2022 and bottomed at $1500.0 in Q1 2021.
  • The 5-year median for Receivables is $148045.0 (2023), against an average of $322106.2.
  • The largest annual shift saw Receivables plummeted 99.45% in 2021 before it soared 71543.33% in 2022.
  • A 5-year view of Receivables shows it stood at $112718.0 in 2021, then soared by 124.28% to $252804.0 in 2022, then crashed by 39.66% to $152532.0 in 2023, then soared by 311.94% to $628340.0 in 2024, then skyrocketed by 52.14% to $955957.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Receivables are $955957.0 (Q3 2025), $204970.0 (Q2 2025), and $265326.0 (Q1 2025).